{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:03Z","timestamp":1789596363141,"version":"build-2803163510"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM25\/00250"],"award-info":[{"award-number":["CM25\/00250"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM25\/00243"],"award-info":[{"award-number":["CM25\/00243"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR24\/00034"],"award-info":[{"award-number":["JR24\/00034"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Echinocandins are the first\u2010line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once\u2010weekly intravenous administration, offering potential advantages in complex clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to describe our real\u2010world experience with rezafungin for the treatment of invasive fungal disease (IFD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 13 patients (mean age: 59.4\u2009\u00b1\u200917.8\u2009years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical intervention (38.5%). Most frequent\n                      <jats:italic>Candida<\/jats:italic>\n                      species were\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>C. albicans<\/jats:italic>\n                      <\/jats:styled-content>\n                      (38.5%),\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>C. parapsilosis<\/jats:italic>\n                      <\/jats:styled-content>\n                      (30.8%) and\n                      <jats:italic>Nakaseomyces glabratus<\/jats:italic>\n                      (15.4%). One patient had necrotizing gingival infection due to\n                      <jats:italic>Trichoderma longibrachiatum.<\/jats:italic>\n                      Main types of IFD included intravascular\n                      <jats:italic>Candida<\/jats:italic>\n                      infection (38.5%) and surgical\u2010site and intra\u2010abdominal candidiasis (23.1% each). Reported reasons for initiating rezafungin were the presence of fluconazole\u2010resistant isolates (53.8%), facilitating outpatient antifungal therapy (30.8%) and avoiding anticipated drug\u2013drug interactions with triazoles (15.4%). No patient received rezafungin as a first\u2010line treatment and most (92.3%) had been previously exposed to other echinocandins. Rezafungin was typically initiated upon clearance of follow\u2010up blood cultures (80.0%). Median number of weekly doses was 4.0 (interquartile range: 3.0\u20135.5). Clinical cure (complete or partial response) by day +30 was achieved in all evaluable patients (100.0% [12\/12]), with no treatment\u2010emergent adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rezafungin was effective and safe as salvage or consolidation therapy in patients with IFD, including deep\u2010seated candidiasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/myc.70163","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:03:36Z","timestamp":1771599816000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real\u2010World Clinical Practice"],"prefix":"10.1111","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-0819","authenticated-orcid":false,"given":"Jorge","family":"Bo\u00e1n","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1497-8770","authenticated-orcid":false,"given":"Eduardo","family":"Aparicio\u2010Minguij\u00f3n","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-8001","authenticated-orcid":false,"given":"Mario","family":"Fern\u00e1ndez\u2010Ruiz","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"},{"name":"School of Medicine Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-2337","authenticated-orcid":false,"given":"Mar\u00eda Asunci\u00f3n","family":"P\u00e9rez\u2010Jacoiste As\u00edn","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"},{"name":"School of Medicine Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-5748","authenticated-orcid":false,"given":"Isabel","family":"Rodr\u00edguez\u2010Goncer","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"},{"name":"School of Medicine Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5333-7529","authenticated-orcid":false,"given":"Francisco","family":"L\u00f3pez\u2010Medrano","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"},{"name":"School of Medicine Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-1991","authenticated-orcid":false,"given":"Rafael","family":"San\u2010Juan","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"},{"name":"School of Medicine Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8765-3466","authenticated-orcid":false,"given":"Jos\u00e9 Tiago","family":"Silva","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"},{"name":"School of Medicine Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-6279","authenticated-orcid":false,"given":"Ana","family":"P\u00e9rez\u2010Ayala","sequence":"additional","affiliation":[{"name":"School of Medicine Universidad Complutense  Madrid Spain"},{"name":"Department of Microbiology Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-653X","authenticated-orcid":false,"given":"Jose Manuel","family":"Caro\u2010Teller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-8255","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)  Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) Instituto de Salud Carlos III (ISCIII)  Madrid Spain"},{"name":"School of Medicine Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(23)00692\u20108"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.04.024"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(22)00872\u20106"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046\u2010024\u201000871\u20100"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2025.101588"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2019.07.002"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(03)14472\u20108"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469\u20100691.12039"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(24)00749\u20107"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00399\u201019"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585270\u2010000000000\u201000000"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.09.019"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010024\u201002134\u20100"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046\u2010023\u201000776\u20104"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001611\u20100"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040262"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)02324\u20108"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(23)00551\u20100"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.546"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae415"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106435"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2025.e02232"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf234"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/asmcr.00114\u201025"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00750\u201024"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2025.e02233"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.70114"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf034"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121\u2010025\u201001120\u20107"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/590566"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1008"},{"key":"e_1_2_10_35_1","unstructured":"J.Guinea J.Meletiadis S.Arikan\u2010Akdagli et\u00a0al. \u201cMethod for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts. EUCAST E \u201d(2023) https:\/\/www.eucast.org\/fileadmin\/eucast\/pdf\/AFST\/methodology\/EUCAST_E.Def_7.4_Yeast_definitive_revised_2023."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/20499361251403060"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.021"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02438\u201019"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701\u201016"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf143"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01339\u201023"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac206"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00959\u201010"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1773\u20101780.2002"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MB\u20100008\u20102014"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00137\u201025"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac235"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099\u201020"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.70163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.70163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.70163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:13:44Z","timestamp":1773220424000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.70163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/myc.70163"],"URL":"https:\/\/doi.org\/10.1111\/myc.70163","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2026-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70163"}}